XNCR
Xencor Inc
Overview
Xencor designs engineered antibody therapeutics to treat cancer and autoimmune diseases. The company uses protein engineering to create XmAb drug candidates with improved properties and multi-target mechanisms, advancing them through clinical trials while partnering with pharmaceutical companies to develop and commercialize certain programs.
Xencor Inc is a Healthcare company operating in Biotechnology with a $1.04B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2023Earnings2024-02-2816 Q&A exchanges
- Q3 FY2023Earnings2023-11-0830 Q&A exchanges
- Q2 FY2023Earnings2023-08-0626 Q&A exchanges
- Q1 FY2023Earnings2023-05-0821 Q&A exchanges
- Q4 FY2022Earnings2023-02-2337 Q&A exchanges
- Q3 FY2022Earnings2022-11-0744 Q&A exchanges
- Q2 FY2022Earnings2022-08-0330 Q&A exchanges
- Q1 FY2022Earnings2022-05-0836 Q&A exchanges
- Q4 FY2021Earnings2022-02-2328 Q&A exchanges
- Q3 FY2021Earnings2021-11-0826 Q&A exchanges
- Q2 FY2021Earnings2021-08-0519 Q&A exchanges
- Q1 FY2021Earnings2021-05-0817 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $-0.83—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $-0.83 | — | — | — | — | EODHD |
Source: EODHD. XNCR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks XNCR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $5.26 | $3.79 | +38.8% | +0.9% | -1.3% |
| Q4 FY2023 | $5.10 | $3.73 | +36.6% | +0.8% | 0.0% |
| Q3 FY2023 | $5.47 | $3.80 | +43.9% | -1.6% | -2.6% |
| Q2 FY2023 | $5.43 | $3.92 | +38.5% | -0.7% | -2.3% |
| Q1 FY2022 | $5.34 | $3.82 | +39.9% | -0.5% | +0.3% |
| Q4 FY2022 | $5.21 | $3.82 | +36.4% | -0.1% | +2.9% |
| Q3 FY2022 | $5.21 | $3.85 | +35.3% | -2.8% | -2.4% |
| Q2 FY2022 | $5.50 | $3.97 | +38.5% | +7.2% | +9.6% |
| Q1 FY2021 | $5.98 | $4.09 | +46.3% | +1.1% | -1.6% |
| Q4 FY2021 | $5.78 | $4.07 | +42.1% | +6.5% | +6.5% |
Guidance change history
Sample- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
- Q1 FY2022Raised2022-04-15
- Q4 FY2022Raised2022-13-15
- Q3 FY2022Raised2022-10-15
- Q2 FY2022Raised2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Bassil I DahiyatCEO1 yr 7 mo12 callsCurrentSample
CEO since 2024 • 1/2 beats (50%) • last call held guidance Q2 FY2023
- Bart Jan CornelissenCFO1 yr 3 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2023
- John R DesjarlaisSR. VICE PRESIDENT & CSO1 yr 7 mo10 callsCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • guidance suspended Q3 FY2023
- Celia EckertSVP, GENERAL COUNSEL1 yr 3 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 1/2 beats (50%) • last call held guidance Q3 FY2023
- Nancy ValenteEVP, Chief Development Officer2 mo3 callsFormerSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • guidance suspended Q3 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XNCR.
$ curl https://api.spokenalpha.com/v1/companies/XNCRFAQ
Frequently asked about XNCR
Where can I find Xencor Inc's (XNCR) earnings call transcripts?
Spoken Alpha indexes XNCR's earnings call transcripts at https://spokenalpha.com/companies/XNCR. Each call links to attributed speakers and parsed analyst Q&A. Xencor Inc's own investor relations page is at https://investors.xencor.com/.
When was Xencor Inc's most recent earnings call?
Xencor Inc (XNCR) held its most recent earnings call on 2024-02-28, covering fiscal Q4 2023.
What sector is XNCR in?
Xencor Inc (XNCR) operates in the Healthcare sector (Biotechnology industry).